Barclays Adjusts Medtronic (MDT) Forecast After Encouraging Earnings Report

On November 20, Barclays elevated its price target for Medtronic plc (NYSE:MDT) from $109 to $111, maintaining an Overweight rating following a robust quarterly performance that surpassed expectations. This adjustment reflects a boosted outlook and heightened earnings estimates as detailed by reporting services.

For the second quarter of fiscal 2026, which concluded on October 24, Medtronic reported impressive sales of $9 billion—a 6.6% increase from the same quarter the previous year. Adjusted earnings per share (EPS) rose by 8% year-on-year to hit $1.36. These figures, while modest in isolation, underscore a commendable performance for a leader in medical devices, with both revenue and EPS outpacing analyst forecasts as well as the company’s own guidance.

A significant driver of this success was the cardiovascular segment, which generated $3.4 billion in revenue, showcasing a remarkable year-over-year increase of 10.8%. This growth not only eclipsed that of the company’s smaller diabetes care unit but also marked the fastest growth rate in the cardiovascular segment outside of pandemic-related dynamics within more than a decade.

Continuing its legacy of innovation, Medtronic is recognized for its relentless product launches and maintains an expansive portfolio of hundreds of devices. This breadth of offerings is instrumental in generating steady revenue streams, earnings, and free cash flow, thereby solidifying the company’s appeal as an investment.

While acknowledging Medtronic’s potential as a valuable investment, there are sentiments that certain artificial intelligence stocks may present greater upside potential with reduced downside risks. For those seeking a deeply undervalued AI stock poised to benefit from tariff trends and onshoring processes, insights into leading options are readily available through dedicated reports.

Source: finance.yahoo.com/news/barclays-adjusts-medtronic-mdt-forecast-191143790.html